Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) EPS (Weighted Average and Diluted) (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with $0.04 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 136.36% to $0.04 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.18 through Dec 2025, up 137.5% year-over-year, with the annual reading at $0.19 for FY2025, 140.43% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.04 at BeOne Medicines, down from $0.08 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.15 in Q3 2023, with the low at -$0.49 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.19, with a median of -$0.26 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 760.0% in 2022, then soared 188.89% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.49 in 2021, then surged by 32.65% to -$0.33 in 2022, then grew by 18.18% to -$0.27 in 2023, then skyrocketed by 59.26% to -$0.11 in 2024, then surged by 136.36% to $0.04 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $0.04, $0.08, and $0.06 for Q4 2025, Q3 2025, and Q2 2025 respectively.